Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.
Identifieur interne : 000195 ( Main/Exploration ); précédent : 000194; suivant : 000196Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.
Auteurs : Rene Garcia-Contreras [Japon] ; Rogelio J. Scougall-Vilchis ; Rosalia Contreras-Bulnes ; Yumiko Kanda ; Hiroshi Nakajima ; Hiroshi SakagamiSource :
- In vivo (Athens, Greece) [ 1791-7549 ]
Descripteurs français
- KwdFr :
- Cellules cultivées (MeSH), Dinoprostone (biosynthèse), Enfant (MeSH), Femelle (MeSH), Fibroblastes (effets des médicaments et des substances chimiques), Fibroblastes (métabolisme), Gencive (cytologie), Humains (MeSH), Interleukine-1 bêta (pharmacologie), Lipopolysaccharides (pharmacologie), Nanoparticules métalliques (administration et posologie), Nanoparticules métalliques (effets indésirables), Survie cellulaire (effets des médicaments et des substances chimiques), Systèmes de délivrance de médicaments (MeSH), Titane (MeSH).
- MESH :
- administration et posologie : Nanoparticules métalliques.
- biosynthèse : Dinoprostone.
- cytologie : Gencive.
- effets des médicaments et des substances chimiques : Fibroblastes, Survie cellulaire.
- effets indésirables : Nanoparticules métalliques.
- métabolisme : Fibroblastes.
- pharmacologie : Interleukine-1 bêta, Lipopolysaccharides.
- Cellules cultivées, Enfant, Femelle, Humains, Systèmes de délivrance de médicaments, Titane.
English descriptors
- KwdEn :
- Cell Survival (drug effects), Cells, Cultured (MeSH), Child (MeSH), Dinoprostone (biosynthesis), Drug Delivery Systems (MeSH), Female (MeSH), Fibroblasts (drug effects), Fibroblasts (metabolism), Gingiva (cytology), Humans (MeSH), Interleukin-1beta (pharmacology), Lipopolysaccharides (pharmacology), Metal Nanoparticles (administration & dosage), Metal Nanoparticles (adverse effects), Titanium (MeSH).
- MESH :
- chemical , biosynthesis : Dinoprostone.
- administration & dosage : Metal Nanoparticles.
- adverse effects : Metal Nanoparticles.
- cytology : Gingiva.
- drug effects : Cell Survival, Fibroblasts.
- metabolism : Fibroblasts.
- chemical , pharmacology : Interleukin-1beta, Lipopolysaccharides.
- Cells, Cultured, Child, Drug Delivery Systems, Female, Humans, Titanium.
Abstract
BACKGROUND
Despite recent progress in the research of nanoparticles (NPs) spanning in many scientific fields, study of NPs in dentistry is limited. This triggered us to investigate the effect of TiO2 NPs on the drug-sensitivity of oral squamous cell carcinoma and inflammation of human gingival fibroblasts (HGFs).
MATERIALS AND METHODS
The number of viable HGF cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Prostaglandin E2 (PGE2) was quantified by enzyme-linked immunosorbent assay. Contamination with lipopolysaccharide (LPS) was assayed by the endotoxin assay kit. Intracellular uptake and distribution of TiO2 NPs were assessed by transmission electron microscopy.
RESULTS
TiO2 NPs (0.05-3.2 mM) did not affect HGF cell viability, although TiO2 NPs clusters were dose-dependently incorporated into the vacuoles of cells. Interleukin-1β (IL-1β) (3 ng/ml) stimulated the secretion of PGE2 into the culture medium by HGF cells. TiO2 NPs also induced PGE2 production, in synergy with IL-1β. Since only a minor amount of LPS was detected in TiO2 NPs, the enhanced production of PGE2 was not simply due to LPS contamination.
CONCLUSION
The present study demonstrates, for the first time to our knowledge, that TiO2 NPs at concentrations higher than 0.2 mM exert an pro-inflammatory action against HGF cells, regardless of the presence or absence of IL-1β.
PubMed: 24632976
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.</title><author><name sortKey="Garcia Contreras, Rene" sort="Garcia Contreras, Rene" uniqKey="Garcia Contreras R" first="Rene" last="Garcia-Contreras">Rene Garcia-Contreras</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan. sakagami@dent.meikai.ac.jp/dentist.garcia@gmail.com.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283</wicri:regionArea><wicri:noRegion>Saitama 350-0283</wicri:noRegion></affiliation></author><author><name sortKey="Scougall Vilchis, Rogelio J" sort="Scougall Vilchis, Rogelio J" uniqKey="Scougall Vilchis R" first="Rogelio J" last="Scougall-Vilchis">Rogelio J. Scougall-Vilchis</name></author><author><name sortKey="Contreras Bulnes, Rosalia" sort="Contreras Bulnes, Rosalia" uniqKey="Contreras Bulnes R" first="Rosalia" last="Contreras-Bulnes">Rosalia Contreras-Bulnes</name></author><author><name sortKey="Kanda, Yumiko" sort="Kanda, Yumiko" uniqKey="Kanda Y" first="Yumiko" last="Kanda">Yumiko Kanda</name></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name></author><author><name sortKey="Sakagami, Hiroshi" sort="Sakagami, Hiroshi" uniqKey="Sakagami H" first="Hiroshi" last="Sakagami">Hiroshi Sakagami</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014 Mar-Apr</date><idno type="RBID">pubmed:24632976</idno><idno type="pmid">24632976</idno><idno type="wicri:Area/Main/Corpus">000213</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000213</idno><idno type="wicri:Area/Main/Curation">000213</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000213</idno><idno type="wicri:Area/Main/Exploration">000213</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.</title><author><name sortKey="Garcia Contreras, Rene" sort="Garcia Contreras, Rene" uniqKey="Garcia Contreras R" first="Rene" last="Garcia-Contreras">Rene Garcia-Contreras</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan. sakagami@dent.meikai.ac.jp/dentist.garcia@gmail.com.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283</wicri:regionArea><wicri:noRegion>Saitama 350-0283</wicri:noRegion></affiliation></author><author><name sortKey="Scougall Vilchis, Rogelio J" sort="Scougall Vilchis, Rogelio J" uniqKey="Scougall Vilchis R" first="Rogelio J" last="Scougall-Vilchis">Rogelio J. Scougall-Vilchis</name></author><author><name sortKey="Contreras Bulnes, Rosalia" sort="Contreras Bulnes, Rosalia" uniqKey="Contreras Bulnes R" first="Rosalia" last="Contreras-Bulnes">Rosalia Contreras-Bulnes</name></author><author><name sortKey="Kanda, Yumiko" sort="Kanda, Yumiko" uniqKey="Kanda Y" first="Yumiko" last="Kanda">Yumiko Kanda</name></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name></author><author><name sortKey="Sakagami, Hiroshi" sort="Sakagami, Hiroshi" uniqKey="Sakagami H" first="Hiroshi" last="Sakagami">Hiroshi Sakagami</name></author></analytic><series><title level="j">In vivo (Athens, Greece)</title><idno type="eISSN">1791-7549</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Survival (drug effects)</term><term>Cells, Cultured (MeSH)</term><term>Child (MeSH)</term><term>Dinoprostone (biosynthesis)</term><term>Drug Delivery Systems (MeSH)</term><term>Female (MeSH)</term><term>Fibroblasts (drug effects)</term><term>Fibroblasts (metabolism)</term><term>Gingiva (cytology)</term><term>Humans (MeSH)</term><term>Interleukin-1beta (pharmacology)</term><term>Lipopolysaccharides (pharmacology)</term><term>Metal Nanoparticles (administration & dosage)</term><term>Metal Nanoparticles (adverse effects)</term><term>Titanium (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cellules cultivées (MeSH)</term><term>Dinoprostone (biosynthèse)</term><term>Enfant (MeSH)</term><term>Femelle (MeSH)</term><term>Fibroblastes (effets des médicaments et des substances chimiques)</term><term>Fibroblastes (métabolisme)</term><term>Gencive (cytologie)</term><term>Humains (MeSH)</term><term>Interleukine-1 bêta (pharmacologie)</term><term>Lipopolysaccharides (pharmacologie)</term><term>Nanoparticules métalliques (administration et posologie)</term><term>Nanoparticules métalliques (effets indésirables)</term><term>Survie cellulaire (effets des médicaments et des substances chimiques)</term><term>Systèmes de délivrance de médicaments (MeSH)</term><term>Titane (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Dinoprostone</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Metal Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Nanoparticules métalliques</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Metal Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Dinoprostone</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Gencive</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Gingiva</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term><term>Fibroblasts</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Fibroblastes</term><term>Survie cellulaire</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Nanoparticules métalliques</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Fibroblasts</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Fibroblastes</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Interleukine-1 bêta</term><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Interleukin-1beta</term><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cells, Cultured</term><term>Child</term><term>Drug Delivery Systems</term><term>Female</term><term>Humans</term><term>Titanium</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules cultivées</term><term>Enfant</term><term>Femelle</term><term>Humains</term><term>Systèmes de délivrance de médicaments</term><term>Titane</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Despite recent progress in the research of nanoparticles (NPs) spanning in many scientific fields, study of NPs in dentistry is limited. This triggered us to investigate the effect of TiO2 NPs on the drug-sensitivity of oral squamous cell carcinoma and inflammation of human gingival fibroblasts (HGFs).</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>The number of viable HGF cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Prostaglandin E2 (PGE2) was quantified by enzyme-linked immunosorbent assay. Contamination with lipopolysaccharide (LPS) was assayed by the endotoxin assay kit. Intracellular uptake and distribution of TiO2 NPs were assessed by transmission electron microscopy.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>TiO2 NPs (0.05-3.2 mM) did not affect HGF cell viability, although TiO2 NPs clusters were dose-dependently incorporated into the vacuoles of cells. Interleukin-1β (IL-1β) (3 ng/ml) stimulated the secretion of PGE2 into the culture medium by HGF cells. TiO2 NPs also induced PGE2 production, in synergy with IL-1β. Since only a minor amount of LPS was detected in TiO2 NPs, the enhanced production of PGE2 was not simply due to LPS contamination.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The present study demonstrates, for the first time to our knowledge, that TiO2 NPs at concentrations higher than 0.2 mM exert an pro-inflammatory action against HGF cells, regardless of the presence or absence of IL-1β.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24632976</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><MedlineDate>2014 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.</ArticleTitle><Pagination><MedlinePgn>217-22</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite recent progress in the research of nanoparticles (NPs) spanning in many scientific fields, study of NPs in dentistry is limited. This triggered us to investigate the effect of TiO2 NPs on the drug-sensitivity of oral squamous cell carcinoma and inflammation of human gingival fibroblasts (HGFs).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The number of viable HGF cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Prostaglandin E2 (PGE2) was quantified by enzyme-linked immunosorbent assay. Contamination with lipopolysaccharide (LPS) was assayed by the endotoxin assay kit. Intracellular uptake and distribution of TiO2 NPs were assessed by transmission electron microscopy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TiO2 NPs (0.05-3.2 mM) did not affect HGF cell viability, although TiO2 NPs clusters were dose-dependently incorporated into the vacuoles of cells. Interleukin-1β (IL-1β) (3 ng/ml) stimulated the secretion of PGE2 into the culture medium by HGF cells. TiO2 NPs also induced PGE2 production, in synergy with IL-1β. Since only a minor amount of LPS was detected in TiO2 NPs, the enhanced production of PGE2 was not simply due to LPS contamination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study demonstrates, for the first time to our knowledge, that TiO2 NPs at concentrations higher than 0.2 mM exert an pro-inflammatory action against HGF cells, regardless of the presence or absence of IL-1β.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Contreras</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan. sakagami@dent.meikai.ac.jp/dentist.garcia@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scougall-Vilchis</LastName><ForeName>Rogelio J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Contreras-Bulnes</LastName><ForeName>Rosalia</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kanda</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sakagami</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>15FIX9V2JP</RegistryNumber><NameOfSubstance UI="C009495">titanium dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>D1JT611TNE</RegistryNumber><NameOfSubstance UI="D014025">Titanium</NameOfSubstance></Chemical><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005881" MajorTopicYN="N">Gingiva</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053768" MajorTopicYN="Y">Metal Nanoparticles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014025" MajorTopicYN="Y">Titanium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytotoxicity</Keyword><Keyword MajorTopicYN="N">Interleukin-1β</Keyword><Keyword MajorTopicYN="N">LPS contamination</Keyword><Keyword MajorTopicYN="N">TiO2 nanoparticles</Keyword><Keyword MajorTopicYN="N">prostaglandin E2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24632976</ArticleId><ArticleId IdType="pii">28/2/217</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Contreras Bulnes, Rosalia" sort="Contreras Bulnes, Rosalia" uniqKey="Contreras Bulnes R" first="Rosalia" last="Contreras-Bulnes">Rosalia Contreras-Bulnes</name><name sortKey="Kanda, Yumiko" sort="Kanda, Yumiko" uniqKey="Kanda Y" first="Yumiko" last="Kanda">Yumiko Kanda</name><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><name sortKey="Sakagami, Hiroshi" sort="Sakagami, Hiroshi" uniqKey="Sakagami H" first="Hiroshi" last="Sakagami">Hiroshi Sakagami</name><name sortKey="Scougall Vilchis, Rogelio J" sort="Scougall Vilchis, Rogelio J" uniqKey="Scougall Vilchis R" first="Rogelio J" last="Scougall-Vilchis">Rogelio J. Scougall-Vilchis</name></noCountry><country name="Japon"><noRegion><name sortKey="Garcia Contreras, Rene" sort="Garcia Contreras, Rene" uniqKey="Garcia Contreras R" first="Rene" last="Garcia-Contreras">Rene Garcia-Contreras</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000195 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000195 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24632976
|texte= Induction of prostaglandin E2 production by TiO2 nanoparticles in human gingival fibroblast.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24632976" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |